Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

U.S. FDA Says Agency Hasn’t Approved Ranbaxy’s Generic Lipitor

Nov. 30 (Bloomberg) -- The Food and Drug Administration hasn’t approved Ranbaxy Laboratories Ltd.’s generic version of Pfizer Inc.’s $10.7 billion Lipitor cholesterol pill, Sandy Walsh, a spokeswoman for the agency, said.

An FDA vendor made a mistake and a statement from the agency announcing the approval of Ranbaxy’s generic drug was distributed in error, Walsh said in an e-mail.

To contact the reporter on this story: Anna Edney in Washington at

To contact the editor responsible for this story: Adriel Bettelheim at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.